Evidence map›Paper›PMID 41453486›Full record

ArticleProgress in neuro-psychopharmacology & biological psychiatry2026

The striatal heterogeneous nuclear ribonucleoprotein H1 mRNA targetome associated with methamphetamine administration and behavior.

Qiu T Ruan, William B Lynch, Rebecca H Cole, Michael A Rieger, Britahny M Baskin, Sophia A Miracle, Jacob A Beierle, Emily J Yao, Jiayi W Cox, Amarpreet Kandola and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Progress in neuro-psychopharmacology & biological psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Qiu T RuanDepartment of Pharmacology, Physiology and Biophysics, Boston University Chobanian and Avedisian School of Medicine, 72 E. Concord St., Boston, MA 02118, USA; Laboratory of Addiction Genetics, Current Location: Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, 140 The Fenway, X138, Boston, MA 02115, USA; Transformative Training Program in Addiction Science, Boston University Chobanian and Avedisian School of Medicine, 72 E. Concord St., Boston, MA 02118, USA.
William B LynchLaboratory of Addiction Genetics, Current Location: Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, 140 The Fenway, X138, Boston, MA 02115, USA; Transformative Training Program in Addiction Science, Boston University Chobanian and Avedisian School of Medicine, 72 E. Concord St., Boston, MA 02118, USA; Graduate Program for Neuroscience, Boston University, One Silber Way, Boston, MA 02215, USA.
Rebecca H ColeLaboratory of Addiction Genetics, Current Location: Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, 140 The Fenway, X138, Boston, MA 02115, USA.
Michael A RiegerDepartment of Genetics, Department of Psychiatry, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA.
Britahny M BaskinLaboratory of Addiction Genetics, Current Location: Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, 140 The Fenway, X138, Boston, MA 02115, USA; NIH/NIDA T32 Training Program on Development of Medications for Substance Use Disorder, Center for Drug Discovery, Northeastern University, 140 The Fenway, Boston, MA 02115, USA.
Sophia A MiracleLaboratory of Addiction Genetics, Current Location: Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, 140 The Fenway, X138, Boston, MA 02115, USA; Graduate Program for Neuroscience, Boston University, One Silber Way, Boston, MA 02215, USA.
Jacob A BeierleDepartment of Pharmacology, Physiology and Biophysics, Boston University Chobanian and Avedisian School of Medicine, 72 E. Concord St., Boston, MA 02118, USA; Laboratory of Addiction Genetics, Current Location: Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, 140 The Fenway, X138, Boston, MA 02115, USA; Transformative Training Program in Addiction Science, Boston University Chobanian and Avedisian School of Medicine, 72 E. Concord St., Boston, MA 02118, USA.
Emily J YaoLaboratory of Addiction Genetics, Current Location: Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, 140 The Fenway, X138, Boston, MA 02115, USA.
Jiayi W CoxLaboratory of Addiction Genetics, Current Location: Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, 140 The Fenway, X138, Boston, MA 02115, USA; Transformative Training Program in Addiction Science, Boston University Chobanian and Avedisian School of Medicine, 72 E. Concord St., Boston, MA 02118, USA; Ph.D. Program in Biomedical Sciences, Graduate Program in Genetics and Genomics, Boston University Chobanian and Avedisian School of Medicine, 72 E. Concord St., Boston, MA 02118, USA.
Amarpreet KandolaLaboratory of Addiction Genetics, Current Location: Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, 140 The Fenway, X138, Boston, MA 02115, USA.
Kayla T RichardsonLaboratory of Addiction Genetics, Current Location: Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, 140 The Fenway, X138, Boston, MA 02115, USA.
Melanie M ChenLaboratory of Addiction Genetics, Current Location: Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, 140 The Fenway, X138, Boston, MA 02115, USA.
Julia C BillupsLaboratory of Addiction Genetics, Current Location: Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, 140 The Fenway, X138, Boston, MA 02115, USA.
R Keith BabbsLaboratory of Addiction Genetics, Current Location: Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, 140 The Fenway, X138, Boston, MA 02115, USA.
Peter E A AshLaboratory of Neurodegeneration, Department of Anatomy and Neurobiology and Neurology, Boston University Chobanian and Avedisian School of Medicine, 72 E. Concord St., Boston, MA 02118, USA.
Benjamin WolozinLaboratory of Neurodegeneration, Department of Anatomy and Neurobiology and Neurology, Boston University Chobanian and Avedisian School of Medicine, 72 E. Concord St., Boston, MA 02118, USA.
Karen K SzumlinskiDepartment of Psychological and Brain Sciences, University of California; #251, Santa Barbara, CA 93106, USA.
W Evan JohnsonDivision of Infectious Disease, Department of Medicine and Center for Data Science, Rutgers University - New Jersey Medical School, 185 South Orange Av., Newark, NJ 07103, USA.
Joseph D DoughertyDepartment of Genetics, Department of Psychiatry, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA.
Camron D BryantDepartment of Pharmacology, Physiology and Biophysics, Boston University Chobanian and Avedisian School of Medicine, 72 E. Concord St., Boston, MA 02118, USA; Laboratory of Addiction Genetics, Current Location: Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, 140 The Fenway, X138, Boston, MA 02115, USA; Transformative Training Program in Addiction Science, Boston University Chobanian and Avedisian School of Medicine, 72 E. Concord St., Boston, MA 02118, USA. Electronic address: c.bryant@northeastern.edu.

Funding

Project-005UL1TR001430 · NCATS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BAIR-MERRITT, MEGAN H, CENTER, DAVID M. · 2015 to 2024
$52.3M
A Reduced Complexity Cross in BALB/c substrains to identify the genetic basis of oxycodone dependence phenotypesU01DA050243 · NIDA · NORTHEASTERN UNIVERSITY · PI BRYANT, CAMRON D, ZACHARIOU, VENETIA · 2020 to 2023
$3.3M
Bridging genetic variation with behavior: Molecular and functional mechanisms of quantitative trait gene regulation of the stimulant and addictive properties of methamphetamine in miceR01DA039168 · NIDA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BRYANT, CAMRON D · 2015 to 2019
$3.0M
Systems genetics of premorbid and cocaine use traits in a rat reduced complexity crossU01DA055299 · NIDA · NORTHEASTERN UNIVERSITY · PI BRYANT, CAMRON D, KANTAK, KATHLEEN M. · 2022 to 2025
$2.8M
BU PREPR25GM125511 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI HENDERSON, ANDREW J, SCHON, KARIN · 2020 to 2024
$1.4M
Training Program on Development of Medications for Substance Use DisorderT32DA055553 · NIDA · NORTHEASTERN UNIVERSITY · PI Raymond G. Booth, Alexandros Makriyannis · 2022 to 2026
$1.3M
The role of Zhx2 in CYP2D regulation, oxycodone metabolism, and opioid addiction model behaviors.F31DA056217 · NIDA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI LYNCH, WILLIAM · 2023 to 2024
$97k
NCATS NIH HHS UL1 TR001430NIDA NIH HHS F31 DA056217NIDA NIH HHS R01 DA039168NIDA NIH HHS T32 DA055553NIDA NIH HHS U01 DA050243NIDA NIH HHS U01 DA055299NIGMS NIH HHS R25 GM125511
6 · The paper itself

Abstract

Methamphetamine addiction remains a major public health concern in the United States that has paralleled the opioid epidemic. Psychostimulant use disorders have a heritable genetic component that remains unexplained. Methamphetamine targets membrane and vesicular transporters to increase synaptic dopamine, norepinephrine, and serotonin. We previously identified Hnrnph1 (heterogeneous nuclear ribonucleoprotein H1) as a quantitative trait gene underlying methamphetamine behavioral sensitivity. Hnrnph1 encodes the RNA-binding protein hnRNP H1 that is ubiquitously expressed in neurons throughout the adult brain. Gene-edited mice with a heterozygous frameshift deletion in Hnrnph1's first coding exon showed reduced methamphetamine-induced dopamine release and behaviors. To potentially inform the mechanism linking hnRNP H with methamphetamine behavior, we surveyed the mRNA targetome of hnRNP H via cross-linking immunoprecipitation coupled with RNA-sequencing in striatum at baseline and at 30 min post-methamphetamine in wild-type female and male C57BL/6 J mice. Methamphetamine induced changes in RNA-binding targets of hnRNP H in mice, including 3'UTRs of enriched mRNAs involved in synaptic plasticity. Targetome, transcriptome, and spliceome analyses triangulated on Cacna2d2 which showed methamphetamine-induced changes in hnRNP H binding, gene expression and splicing. Pre-treatment with pregabalin, an inhibitor of CACNA2D2 and CACNA2D1 voltage-gated calcium channel subunits, attenuated methamphetamine-induced locomotor activity, suggesting CACNA2D2 could contribute to methamphetamine locomotor stimulant sensitivity. Our study identifies a dynamic hnRNP H RNA targetome that can respond rapidly to methamphetamine and could potentially contribute to synaptic plasticity and behavior. Given our discovery-based findings, future studies will require directly validating the link between methamphetamine-induced changes in hnRNP H binding, gene regulation, synaptic plasticity, and behavior.

Indexed as

Central Nervous System StimulantsCorpus StriatumHeterogeneous-Nuclear Ribonucleoprotein Group F-HMethamphetamineRNA, MessengerAnimalsFemaleMaleMiceMice, Inbred C57BLCentral Nervous System StimulantsHeterogeneous-Nuclear Ribonucleoprotein Group F-HMethamphetamineRNA, MessengerAmphetamineCocaineGabapentinLyricaQTL

Identifiers

PMID41453486
PMCPMC12811841

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.